ARCH Venture Partners X, LLC
Insider CIK 1769012 · SNNA 10% owner · ERAS 10% owner · SANA 10% owner · BOLD 10% owner · VERV 10% owner · NMRA 10% owner · PRME 10% owner · ASPE 10% owner
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| ASPE Aspen Neuroscience, Inc. | C Conversion deriv | 2026-11-02 | 2026-11-02 | 214,355 | — | — | 0 | SEC↗ |
| ASPE Aspen Neuroscience, Inc. | C Conversion deriv | 2026-11-02 | 2026-11-02 | 259,948 | — | — | 0 | SEC↗ |
| ASPE Aspen Neuroscience, Inc. | C Conversion deriv | 2026-11-02 | 2026-11-02 | 295,490 | — | — | 0 | SEC↗ |
| ASPE Aspen Neuroscience, Inc. | C Conversion deriv | 2026-11-02 | 2026-11-02 | 295,490 | — | — | 0 | SEC↗ |
| ASPE Aspen Neuroscience, Inc. | C Conversion deriv | 2026-11-02 | 2026-11-02 | 286,304 | — | — | 0 | SEC↗ |
| ASPE Aspen Neuroscience, Inc. | C Conversion deriv | 2026-11-02 | 2026-11-02 | 286,304 | — | — | 0 | SEC↗ |
| ASPE Aspen Neuroscience, Inc. | C Conversion deriv | 2026-11-02 | 2026-11-02 | 298,258 | — | — | 0 | SEC↗ |
| ASPE Aspen Neuroscience, Inc. | C Conversion deriv | 2026-11-02 | 2026-11-02 | 298,258 | — | — | 0 | SEC↗ |
| ASPE Aspen Neuroscience, Inc. | C Conversion deriv | 2026-11-02 | 2026-11-02 | 187,182 | — | — | 0 | SEC↗ |
| ASPE Aspen Neuroscience, Inc. | P Buy | 2026-11-02 | 2026-11-02 | 1,200,000 | $15.00 | $18.00M | 1,200,000 | SEC↗ |
| ASPE Aspen Neuroscience, Inc. | C Conversion | 2026-11-02 | 2026-11-02 | 214,355 | — | — | 1,161,074 | SEC↗ |
| ASPE Aspen Neuroscience, Inc. | C Conversion | 2026-11-02 | 2026-11-02 | 295,490 | — | — | 946,719 | SEC↗ |
| ASPE Aspen Neuroscience, Inc. | C Conversion | 2026-11-02 | 2026-11-02 | 286,304 | — | — | 651,229 | SEC↗ |
| ASPE Aspen Neuroscience, Inc. | C Conversion | 2026-11-02 | 2026-11-02 | 298,258 | — | — | 364,925 | SEC↗ |
| ASPE Aspen Neuroscience, Inc. | P Buy | 2026-11-02 | 2026-11-02 | 66,667 | $15.00 | $1.00M | 66,667 | SEC↗ |
| ASPE Aspen Neuroscience, Inc. | C Conversion | 2026-11-02 | 2026-11-02 | 259,948 | — | — | 1,393,848 | SEC↗ |
| ASPE Aspen Neuroscience, Inc. | C Conversion | 2026-11-02 | 2026-11-02 | 295,490 | — | — | 1,133,900 | SEC↗ |
| ASPE Aspen Neuroscience, Inc. | C Conversion | 2026-11-02 | 2026-11-02 | 286,304 | — | — | 838,410 | SEC↗ |
| ASPE Aspen Neuroscience, Inc. | C Conversion | 2026-11-02 | 2026-11-02 | 298,258 | — | — | 552,106 | SEC↗ |
| ASPE Aspen Neuroscience, Inc. | C Conversion | 2026-11-02 | 2026-11-02 | 187,182 | — | — | 253,848 | SEC↗ |
| ASPE Aspen Neuroscience, Inc. | P Buy | 2026-11-02 | 2026-11-02 | 66,666 | $15.00 | $1000.0K | 66,666 | SEC↗ |
| BOLD Boundless Bio, Inc. | M Exercise deriv | 2026-07-01 | 2026-07-06 | 16,000 | — | $0 | 0 | SEC↗ |
| BOLD Boundless Bio, Inc. | S Sale | 2026-07-01 | 2026-07-06 | 16,000 | $2.49 | $39.8K | 0 | SEC↗ |
| BOLD Boundless Bio, Inc. | M Exercise | 2026-07-01 | 2026-07-06 | 16,000 | $1.03 | $16.5K | 16,000 | SEC↗ |
| NMRA Neumora Therapeutics, Inc. | P Buy | 2025-10-27 | 2025-10-29 | 1,915,700 | $2.61 | $5.00M | 6,046,907 | SEC↗ |
| PRME Prime Medicine, Inc. | P Buy | 2025-08-01 | 2025-08-01 | 3,030,300 | $3.30 | $10.00M | 6,230,300 | SEC↗ |
| BOLD Boundless Bio, Inc. | C Conversion deriv | 2024-04-02 | 2024-04-04 | 201,465 | — | $0 | 0 | SEC↗ |
| BOLD Boundless Bio, Inc. | C Conversion deriv | 2024-04-02 | 2024-04-04 | 164,835 | — | $0 | 0 | SEC↗ |
| BOLD Boundless Bio, Inc. | C Conversion deriv | 2024-04-02 | 2024-04-04 | 227,920 | — | $0 | 0 | SEC↗ |
| BOLD Boundless Bio, Inc. | C Conversion deriv | 2024-04-02 | 2024-04-04 | 454,212 | — | $0 | 0 | SEC↗ |
| BOLD Boundless Bio, Inc. | C Conversion deriv | 2024-04-02 | 2024-04-04 | 586,080 | — | $0 | 0 | SEC↗ |
| BOLD Boundless Bio, Inc. | C Conversion deriv | 2024-04-02 | 2024-04-04 | 424,908 | — | $0 | 0 | SEC↗ |
| BOLD Boundless Bio, Inc. | C Conversion deriv | 2024-04-02 | 2024-04-04 | 366,301 | — | $0 | 0 | SEC↗ |
| BOLD Boundless Bio, Inc. | C Conversion | 2024-04-02 | 2024-04-04 | 589,743 | — | $0 | 617,092 | SEC↗ |
| BOLD Boundless Bio, Inc. | P Buy | 2024-04-02 | 2024-04-04 | 133,333 | $16.00 | $2.13M | 1,181,766 | SEC↗ |
| BOLD Boundless Bio, Inc. | C Conversion | 2024-04-02 | 2024-04-04 | 787,545 | — | $0 | 828,570 | SEC↗ |
| BOLD Boundless Bio, Inc. | C Conversion | 2024-04-02 | 2024-04-04 | 1,048,433 | — | $0 | 1,048,433 | SEC↗ |
| BOLD Boundless Bio, Inc. | P Buy | 2024-04-02 | 2024-04-04 | 66,667 | $16.00 | $1.07M | 683,759 | SEC↗ |
| PRME Prime Medicine, Inc. | P Buy | 2024-02-15 | 2024-02-20 | 3,200,000 | $6.25 | $20.00M | 3,200,000 | SEC↗ |
| SANA Sana Biotechnology, Inc. | P Buy | 2024-02-08 | 2024-02-12 | 363,637 | $5.50 | $2.00M | 10,667,387 | SEC↗ |
| SANA Sana Biotechnology, Inc. | P Buy | 2024-02-08 | 2024-02-12 | 727,272 | $5.50 | $4.00M | 12,446,022 | SEC↗ |
| SANA Sana Biotechnology, Inc. | P Buy | 2024-02-08 | 2024-02-12 | 727,272 | $5.50 | $4.00M | 12,446,022 | SEC↗ |
| NMRA Neumora Therapeutics, Inc. | J Other | 2023-12-08 | 2023-12-12 | 1,176,593 | — | $0 | 2,321,566 | SEC↗ |
| NMRA Neumora Therapeutics, Inc. | J Other | 2023-12-08 | 2023-12-12 | 703,061 | — | $0 | 1,387,228 | SEC↗ |
| NMRA Neumora Therapeutics, Inc. | C Conversion deriv | 2023-09-19 | 2023-09-20 | 6,895,021 | — | $0 | 0 | SEC↗ |
| NMRA Neumora Therapeutics, Inc. | C Conversion deriv | 2023-09-19 | 2023-09-20 | 6,576,400 | — | $0 | 0 | SEC↗ |
| NMRA Neumora Therapeutics, Inc. | C Conversion deriv | 2023-09-19 | 2023-09-20 | 1,144,973 | — | $0 | 0 | SEC↗ |
| NMRA Neumora Therapeutics, Inc. | C Conversion deriv | 2023-09-19 | 2023-09-20 | 684,167 | — | $0 | 0 | SEC↗ |
| NMRA Neumora Therapeutics, Inc. | C Conversion deriv | 2023-09-19 | 2023-09-20 | 2,124,143 | — | $0 | 0 | SEC↗ |
| NMRA Neumora Therapeutics, Inc. | C Conversion deriv | 2023-09-19 | 2023-09-20 | 2,124,143 | — | $0 | 0 | SEC↗ |
| NMRA Neumora Therapeutics, Inc. | C Conversion deriv | 2023-09-19 | 2023-09-20 | 684,167 | — | $0 | 0 | SEC↗ |
| NMRA Neumora Therapeutics, Inc. | C Conversion deriv | 2023-09-19 | 2023-09-20 | 1,144,973 | — | $0 | 0 | SEC↗ |
| NMRA Neumora Therapeutics, Inc. | C Conversion deriv | 2023-09-19 | 2023-09-20 | 6,895,021 | — | $0 | 0 | SEC↗ |
| NMRA Neumora Therapeutics, Inc. | C Conversion deriv | 2023-09-19 | 2023-09-20 | 6,576,400 | — | $0 | 0 | SEC↗ |
| NMRA Neumora Therapeutics, Inc. | C Conversion | 2023-09-19 | 2023-09-20 | 684,167 | — | $0 | 684,167 | SEC↗ |
| NMRA Neumora Therapeutics, Inc. | C Conversion | 2023-09-19 | 2023-09-20 | 1,144,973 | — | $0 | 1,144,973 | SEC↗ |
| NMRA Neumora Therapeutics, Inc. | C Conversion | 2023-09-19 | 2023-09-20 | 6,895,021 | — | $0 | 12,205,379 | SEC↗ |
| NMRA Neumora Therapeutics, Inc. | C Conversion | 2023-09-19 | 2023-09-20 | 6,576,400 | — | $0 | 11,886,758 | SEC↗ |
| NMRA Neumora Therapeutics, Inc. | C Conversion | 2023-09-19 | 2023-09-20 | 2,124,143 | — | $0 | 2,124,143 | SEC↗ |
| NMRA Neumora Therapeutics, Inc. | P Buy | 2023-09-19 | 2023-09-20 | 1,500,000 | $17.00 | $25.50M | 3,624,143 | SEC↗ |
| NMRA Neumora Therapeutics, Inc. | P Buy | 2023-09-19 | 2023-09-20 | 1,500,000 | $17.00 | $25.50M | 3,624,143 | SEC↗ |
| NMRA Neumora Therapeutics, Inc. | C Conversion | 2023-09-19 | 2023-09-20 | 684,167 | — | $0 | 684,167 | SEC↗ |
| NMRA Neumora Therapeutics, Inc. | C Conversion | 2023-09-19 | 2023-09-20 | 1,144,973 | — | $0 | 1,144,973 | SEC↗ |
| NMRA Neumora Therapeutics, Inc. | C Conversion | 2023-09-19 | 2023-09-20 | 6,895,021 | — | $0 | 12,205,379 | SEC↗ |
| NMRA Neumora Therapeutics, Inc. | C Conversion | 2023-09-19 | 2023-09-20 | 2,124,143 | — | $0 | 2,124,143 | SEC↗ |
| NMRA Neumora Therapeutics, Inc. | C Conversion | 2023-09-19 | 2023-09-20 | 6,576,400 | — | $0 | 11,886,758 | SEC↗ |
| PRME Prime Medicine, Inc. | C Conversion deriv | 2022-10-24 | 2022-10-26 | 1,141,474 | — | $0 | 0 | SEC↗ |
| PRME Prime Medicine, Inc. | C Conversion deriv | 2022-10-24 | 2022-10-26 | 16,666,667 | — | $0 | 0 | SEC↗ |
| PRME Prime Medicine, Inc. | C Conversion deriv | 2022-10-24 | 2022-10-26 | 16,666,664 | — | $0 | 0 | SEC↗ |
| PRME Prime Medicine, Inc. | C Conversion deriv | 2022-10-24 | 2022-10-26 | 1,141,474 | — | $0 | 0 | SEC↗ |
| PRME Prime Medicine, Inc. | P Buy | 2022-10-24 | 2022-10-26 | 400,000 | $17.00 | $6.80M | 6,128,297 | SEC↗ |
| PRME Prime Medicine, Inc. | C Conversion | 2022-10-24 | 2022-10-26 | 5,728,297 | — | $0 | 5,728,297 | SEC↗ |
| PRME Prime Medicine, Inc. | C Conversion | 2022-10-24 | 2022-10-26 | 5,728,297 | — | $0 | 5,728,297 | SEC↗ |
| PRME Prime Medicine, Inc. | P Buy | 2022-10-24 | 2022-10-26 | 400,000 | $17.00 | $6.80M | 6,128,297 | SEC↗ |
| ERAS Erasca, Inc. | C Conversion deriv | 2021-07-20 | 2021-07-20 | 2,100,000 | — | $0 | 0 | SEC↗ |
| ERAS Erasca, Inc. | C Conversion deriv | 2021-07-20 | 2021-07-20 | 2,100,000 | — | $0 | 0 | SEC↗ |
| ERAS Erasca, Inc. | C Conversion deriv | 2021-07-20 | 2021-07-20 | 3,400,000 | — | $0 | 0 | SEC↗ |
| ERAS Erasca, Inc. | C Conversion deriv | 2021-07-20 | 2021-07-20 | 1,133,333 | — | $0 | 0 | SEC↗ |
| ERAS Erasca, Inc. | C Conversion deriv | 2021-07-20 | 2021-07-20 | 3,400,000 | — | $0 | 0 | SEC↗ |
| ERAS Erasca, Inc. | C Conversion deriv | 2021-07-20 | 2021-07-20 | 1,133,333 | — | $0 | 0 | SEC↗ |
| ERAS Erasca, Inc. | C Conversion | 2021-07-20 | 2021-07-20 | 5,527,777 | — | $0 | 5,527,777 | SEC↗ |
| ERAS Erasca, Inc. | C Conversion | 2021-07-20 | 2021-07-20 | 5,527,777 | — | $0 | 5,527,777 | SEC↗ |
| VERV Verve Therapeutics, Inc. | C Conversion deriv | 2021-06-21 | 2021-06-23 | 7,107,024 | — | $0 | 0 | SEC↗ |
| VERV Verve Therapeutics, Inc. | C Conversion deriv | 2021-06-21 | 2021-06-23 | 7,107,023 | — | $0 | 0 | SEC↗ |
| VERV Verve Therapeutics, Inc. | C Conversion deriv | 2021-06-21 | 2021-06-23 | 4,508,144 | — | $0 | 0 | SEC↗ |
| VERV Verve Therapeutics, Inc. | C Conversion deriv | 2021-06-21 | 2021-06-23 | 4,508,146 | — | $0 | 0 | SEC↗ |
| VERV Verve Therapeutics, Inc. | C Conversion | 2021-06-21 | 2021-06-23 | 1,254,404 | — | $0 | 1,254,404 | SEC↗ |
| VERV Verve Therapeutics, Inc. | C Conversion | 2021-06-21 | 2021-06-23 | 1,254,405 | — | $0 | 1,254,405 | SEC↗ |
| SANA Sana Biotechnology, Inc. | C Conversion deriv | 2021-02-08 | 2021-02-10 | 781,250 | — | $0 | 0 | SEC↗ |
| SANA Sana Biotechnology, Inc. | C Conversion deriv | 2021-02-08 | 2021-02-10 | 3,687,500 | — | $0 | 0 | SEC↗ |
| SANA Sana Biotechnology, Inc. | C Conversion deriv | 2021-02-08 | 2021-02-10 | 3,687,500 | — | $0 | 0 | SEC↗ |
| SANA Sana Biotechnology, Inc. | C Conversion deriv | 2021-02-08 | 2021-02-10 | 2,343,750 | — | $0 | 0 | SEC↗ |
| SANA Sana Biotechnology, Inc. | C Conversion deriv | 2021-02-08 | 2021-02-10 | 2,343,750 | — | $0 | 0 | SEC↗ |
| SANA Sana Biotechnology, Inc. | C Conversion deriv | 2021-02-08 | 2021-02-10 | 5,687,500 | — | $0 | 0 | SEC↗ |
| SANA Sana Biotechnology, Inc. | C Conversion deriv | 2021-02-08 | 2021-02-10 | 781,250 | — | $0 | 0 | SEC↗ |
| SANA Sana Biotechnology, Inc. | C Conversion deriv | 2021-02-08 | 2021-02-10 | 5,687,500 | — | $0 | 0 | SEC↗ |
| SANA Sana Biotechnology, Inc. | C Conversion deriv | 2021-02-08 | 2021-02-10 | 9,375,000 | — | $0 | 0 | SEC↗ |
| SANA Sana Biotechnology, Inc. | C Conversion deriv | 2021-02-08 | 2021-02-10 | 9,375,000 | — | $0 | 0 | SEC↗ |
| SANA Sana Biotechnology, Inc. | C Conversion | 2021-02-08 | 2021-02-10 | 11,718,750 | — | $0 | 11,718,750 | SEC↗ |
| SANA Sana Biotechnology, Inc. | C Conversion | 2021-02-08 | 2021-02-10 | 10,156,250 | — | $0 | 10,303,750 | SEC↗ |
| SANA Sana Biotechnology, Inc. | C Conversion | 2021-02-08 | 2021-02-10 | 10,156,250 | — | $0 | 10,301,250 | SEC↗ |
| SANA Sana Biotechnology, Inc. | C Conversion | 2021-02-08 | 2021-02-10 | 11,718,750 | — | $0 | 11,718,750 | SEC↗ |
| SNNA Sienna Biopharmaceuticals, | P Buy | 2019-02-22 | 2019-02-26 | 150,000 | $2.50 | $375.0K | 2,900,575 | SEC↗ |
| SNNA Sienna Biopharmaceuticals, | P Buy | 2019-02-22 | 2019-02-26 | 1,865,800 | $2.50 | $4.66M | 1,865,800 | SEC↗ |
| SNNA Sienna Biopharmaceuticals, | P Buy | 2019-02-22 | 2019-02-26 | 150,000 | $2.50 | $375.0K | 1,032,493 | SEC↗ |